In Vitro Safety Pharmacology Profiling Market
完整報告名稱與涵蓋範圍
In Vitro Safety Pharmacology Profiling Market by Product Type (Cell-Based Assays, Organ-Based Assays, Tissue-Based Assays), by Application (Cardiotoxicity Profiling, Neurotoxicity Profiling, Hepatotoxicity Profiling, Nephrotoxicity Profiling, Genotoxicity & Carcinogenicity Assays, Others), by Technology Platform (High-Throughput Screening, Multiparametric Flow Cytometry, Microscopy-Based Assays, Patch Clamp Electrophysiology, Others), by End User (Pharmaceutical and Biotechnology Companies, Contract Research Organizations, Academic and Research Institutions), and by Service Provider [In-House Testing (Pharma Companies), Outsourced Testing (CROs & Labs)] Forecast till 2035
報告摘要
In Vitro Safety Pharmacology Profiling Market by Product Type (Cell-Based Assays, Organ-Based Assays, Tissue-Based Assays), by Application (Cardiotoxicity Profiling, Neurotoxicity Profiling, Hepatotoxicity Profiling, Nephrotoxicity Profiling, Genotoxicity & Carcinogenicity Assays, Others), by Technology Platform (High-Throughput Screening, Multiparametric Flow Cytometry, Microscopy-Based Assays, Patch Clamp Electrophysiology, Others), by End User (Pharmaceutical and Biotechnology Companies, Contract Research Organizations, Academic and Research Institutions), and by Service Provider [In-House Testing (Pharma Companies), Outsourced Testing (CROs & Labs)] Forecast till 2035
Market Overview
The In Vitro Safety Pharmacology Profiling Market is projected to reach USD 5,745.9 million by 2035, growing at a CAGR of 8.4% from 2025 to 2035. In vitro safety pharmacology profiling involves testing drug candidates on cultured cells or tissues to evaluate their potential effects on vital physiological systems, such as the heart, nervous system, and lungs. This helps identify safety risks early in drug development before clinical trials begin.
Innovations in predictive toxicology technologies such as AI, organ-on-a-chip, high-throughput screening, and 3D cell cultures are major factors responsible for the growth of the Global In Vitro Safety Pharmacology Profiling Market. These new technologies not only facilitate the early detection of drug-induced toxicities but also help in reducing the number of animal tests. Besides, they also make safety assessments more accurate, less expensive, and more human-relevant, particularly in the case of biologics and gene therapies.
Key Company Development
In April 2025, Eurofins enhanced its European presence by completing the acquisition of SYNLAB’s clinical diagnostics operations in Spain. Before that, in July 2024, the company bought Labormar in Colombia, broadening its Latin American footprint and turning its focus to the Food and Feed, Environmental, Cosmetic, and Pharmacological testing sectors.
Major Players
Major competitors in the global in vitro safety pharmacology profiling market are Eurofins, ICE Bioscience, WuXi Biology, Charles River Laboratories, Mediford Corporation, Aurigene, Labcorp, Evotec, Creative Biolabs, and Accelera S.r.l.
Report Attribute Details
• Market Size 2024: USD 2,428.0 Million
• Market Size 2035: USD 5,745.9 Million
• CAGR (2025-2035): 8.4%
• Base Year: 2024
• Market Forecast Period: 2025-2035
Market Segmentations
• By Product Type: Cell-Based Assays – 8.2%, Organ-Based Assays – 9.5%.
• By Application: Cardiotoxicity Profiling – 8.1%, Neurotoxicity Profiling – 9.4%.
• By Technology Platform: High-Throughput Screening – 9.1%, Multiparametric Flow Cytometry – 8.9%.
• By End User: Pharmaceutical and Biotechnology Companies – 8.2%, Contract Research Organizations – 9.5%.
• By Service Provider: In-House Testing – 8.2%, Outsourced Testing – 8.7%.
Regional Insights
The North American in vitro safety pharmacology profiling market has been flourishing for the last few years, and it is mainly attributed to the demand for early drug toxicity screening and the rising prevalence of chronic diseases. In 2024, North America dominated the In Vitro Safety Pharmacology Profiling Market, led by the U.S. at USD 726.7 million, followed by Canada at USD 39.9 million.
The in vitro safety pharmacology profiling market in Europe keeps on growing as the continent puts more emphasis on the early stage of drug safety and the reduction of animal testing. The EMA and other regulatory bodies have been urging pharmaceutical companies to resort to predictive in vitro methods for drug toxicity assessment. Europe showed steady growth in 2024, with the UK leading at USD 216.7 million, followed by Germany (USD 169.0 million) and France (USD 140.0 million).
The market in the Asia-Pacific region is booming as a result of increased drug development activities and the establishment of more stringent regulatory frameworks. In vitro testing is being extensively implemented to lessen the number of costly in vivo studies and to expedite the early detection of toxicity. The Asia-Pacific region saw notable market expansion in 2024, with China accounting for USD 147.5 million and Japan USD 100.4 million.
South America’s in vitro safety pharmacology profiling market is steadily growing, driven by increasing pharmaceutical R&D investments and stricter regulations from agencies like ANVISA and INVIMA. Local biotech and pharma firms are turning to in vitro assays to identify drug safety issues before human trials. CROs have become crucial in providing specialized services in cardiac, liver, and CNS toxicity testing.
In the Middle East and Africa, the market is gaining momentum as pharmaceutical R&D investment rises and regulatory reforms promote safer drug development practices. In vitro models are being favored for their cost-effectiveness, speed, and ethical advantages over animal studies. Countries such as the UAE, Saudi Arabia, and South Africa are investing in laboratory infrastructure and local expertise.
授權報價
| Single User Price | $4,950 USD |
| Multi User Licence (up to 10 users) | $5,950 USD |
| Enterprisewide Price (Global Site License) | $7,250 USD |
目錄 Table of Contents
TABLE OF CONTENTS
1 EXECUTIVE SUMMARY ..... 21
1.1 MARKET OVERVIEW: ..... 22
1.2 MARKET SEGMENTATION ....... 22
1.3 COMPETITIVE LANDSCAPE ...... 23
1.4 FUTURE OUTLOOK ..... 23
2 MARKET INTRODUCTION ....... 26
2.1 DEFINITION ...... 26
2.2 SCOPE OF THE STUDY .... 26
2.3 RESEARCH OBJECTIVE ........ 27
2.4 MARKET STRUCTURE .... 27
3 RESEARCH METHODOLOGY ........ 28
3.1 OVERVIEW ........ 28
3.2 DATA FLOW ...... 30
3.2.1 DATA MINING PROCESS ......... 30
3.3 PURCHASED DATABASE: ..... 31
3.4 SECONDARY SOURCES: ........ 32
3.4.1 SECONDARY RESEARCH DATA FLOW: ..... 33
3.5 PRIMARY RESEARCH: ..... 34
3.5.1 PRIMARY RESEARCH DATA FLOW: ..... 35
3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED ..... 36
3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE ........ 36
3.6 APPROACHES FOR MARKET END USER ESTIMATION: ....... 37
3.6.1 REVENUE ANALYSIS APPROACH .... 37
3.6.2 DATA FORECASTING ......... 38
3.6.3 DATA FORECASTING TECHNIQUE .... 38
3.7 DATA MODELING ........ 39
3.7.1 MICROECONOMIC FACTOR ANALYSIS: ..... 39
3.7.2 DATA MODELING: ..... 40
4 MARKET DYNAMICS .... 42
4.1 INTRODUCTION ..... 42
4.2 DRIVERS ....... 43
4.2.1 RISING DRUG ATTRITION RATES & COST OF FAILURES ......... 43
4.2.2 ADVANCEMENTS IN PREDICTIVE TOXICOLOGY TECHNOLOGIES ........ 43
4.2.3 GROWTH IN BIOLOGICS & PERSONALIZED MEDICINE ......... 43
4.2.4 GOVERNMENT & PRIVATE FUNDING FOR ALTERNATIVE TESTING METHODS ...... 44
4.2.5 STRINGENT REGULATORY REQUIREMENTS ...... 44
4.3 RESTRAINTS .... 45
4.3.1 HIGH DEVELOPMENT & OPERATIONAL COSTS ...... 45
4.3.2 LIMITED PREDICTIVE ACCURACY FOR COMPLEX TOXICITY ENDPOINTS ..... 45
4.3.3 LACK OF STANDARDIZATION & REPRODUCIBILITY ISSUES .... 46
4.3.4 SLOW ADOPTION IN EMERGING MARKETS .... 46
4.4 OPPORTUNITY ....... 47
4.4.1 RISING DEMAND FOR EARLY TOXICITY SCREENING ...... 47
4.4.2 INCREASING OUTSOURCING TO CROS .... 47
4.5 IMPACT ANALYSIS OF COVID – 19 ..... 48
5 MARKET FACTOR ANALYSIS ........ 49
5.1 SUPPLY CHAIN ANALYSIS ....... 49
5.1.1 RAW MATERIAL AND REAGENT SUPPLIERS .... 49
5.1.2 ASSAY DEVELOPMENT AND TECHNOLOGY PROVIDERS ....... 50
5.1.3 CONTRACT RESEARCH ORGANIZATIONS (CROS) AND TESTING LABORATORIES ....... 50
5.1.4 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES (END-USERS) ...... 50
5.1.5 REGULATORY BODIES AND MARKET DISTRIBUTION ....... 50
5.2 PORTER’S FIVE FORCES MODEL ......... 51
5.2.1 THREAT OF NEW ENTRANTS ..... 51
5.2.2 BARGAINING POWER OF SUPPLIERS (HIGH) ........ 52
5.2.3 THREAT OF SUBSTITUTES (LOW TO MODERATE) .... 52
5.2.4 BARGAINING POWER OF BUYERS (LOW TO MODERATE) ...... 52
5.2.5 INTENSITY OF RIVALRY (MODERATE TO HIGH) ....... 52
6 GLOBAL IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET , BY PRODUCT TYPE .. 54
6.1 INTRODUCTION ..... 54
6.2 CELL-BASED ASSAYS...... 55
6.3 ORGAN-BASED ASSAYS ....... 55
6.4 TISSUE-BASED ASSAYS ....... 56
7 GLOBAL IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET , BY APPLICATION ...... 57
7.1 INTRODUCTION ..... 57
7.2 CARDIOTOXICITY PROFILING ........ 58
7.3 NEUROTOXICITY PROFILING ......... 58
7.4 HEPATOTOXICITY PROFILING ...... 59
7.5 NEPHROTOXICITY PROFILING ...... 59
7.6 GENOTOXICITY & CARCINOGENICITY ASSAYS..... 59
8 GLOBAL IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY TECHNOLOGY ...... 60
8.1 INTRODUCTION ..... 60
8.2 HIGH-THROUGHPUT SCREENING (HTS) ...... 61
8.3 MULTIPARAMETRIC FLOW CYTOMETRY ........ 61
8.4 MICROSCOPY-BASED ASSAYS ....... 62
8.5 PATCH-CLAMP ELECTROPHYSIOLOGY ....... 62
9 GLOBAL IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET , BY END USER ...... 63
9.1 INTRODUCTION ..... 63
9.2 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES ......... 64
9.3 CONTRACT RESEARCH ORGANIZATIONS (CROS) ....... 64
9.4 ACADEMIC AND RESEARCH INSTITUTIONS .... 64
10 GLOBAL IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET , BY SERVICE PROVIDER
10.1 INTRODUCTION ..... 65
10.2 IN-HOUSE TESTING (PHARMA COMPANIES) ........ 66
10.3 OUTSOURCED TESTING (CROS & LABS) ........ 66
11 GLOBAL IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET , BY REGION .... 67
11.1 GLOBAL ........ 67
11.2 NORTH AMERICA ....... 68
11.2.1 USA ......... 73
11.2.2 CANADA ........ 75
11.3 EUROPE ........ 78
11.3.1 UNITED KINGDOM..... 84
11.3.2 GERMANY ......... 86
11.3.3 FRANCE ...... 88
11.3.4 ITALY ....... 90
11.3.5 SPAIN ....... 92
11.3.6 RUSSIA .... 94
11.3.7 REST OF EUROPE ....... 96
11.4 ASIA PACIFIC ......... 98
11.4.1 CHINA........ 104
11.4.2 SOUTH KOREA ......... 106
11.4.3 INDIA ........ 108
11.4.4 JAPAN ..... 110
11.4.5 INDONESIA ....... 112
11.4.6 MALAYSIA ........ 114
11.4.7 THAILAND .... 116
11.4.8 REST OF ASIA PACIFIC ...... 118
11.5 SOUTH AMERICA ....... 120
11.5.1 BRAZIL ....... 126
11.5.2 MEXICO ..... 128
11.5.3 ARGENTINA........ 130
11.5.4 REST OF SOUTH AMERICA ........ 132
11.6 MIDDLE EAST AND AFRICA ...... 133
11.6.1 GCC COUNTRIES ....... 140
11.6.2 SOUTH AFRICA .... 142
11.6.3 REST OF MIDDLE EAST & AFRICA (MEA) ....... 144
12 COMPETITIVE LANDSCAPE .... 146
12.1 INTRODUCTION ..... 146
12.2 MARKET SHARE ANALYSIS, 2024 ..... 147
12.3 COMPETITOR DASHBOARD....... 148
13 COMPANY PROFILES ........ 149
13.1 EUROFINS .... 149
13.1.1 COMPANY OVERVIEW ....... 149
13.1.2 PRODUCTS OFFERED ........ 150
13.1.3 KEY DEVELOPMENTS ........ 150
13.1.4 SWOT ANALYSIS ........ 151
13.1.5 FINANCIAL ANALYSIS ........ 152
13.1.6 KEY STRATEGY ......... 152
13.2 ICE BIOSCIENCE .... 153
13.2.1 COMPANY OVERVIEW ....... 153
13.2.2 PRODUCTS OFFERED ........ 154
13.2.3 SWOT ANALYSIS ........ 154
13.2.4 FINANCIAL ANALYSIS ........ 155
13.2.5 KEY STRATEGY ......... 155
13.3 WUXI BIOLOGY ...... 156
13.3.1 COMPANY OVERVIEW ....... 156
13.3.2 PRODUCTS OFFERED ........ 157
13.3.3 SWOT ANALYSIS ........ 157
13.3.4 FINANCIAL ANALYSIS ........ 158
13.3.5 KEY STRATEGY ......... 158
13.4 CHARLES RIVER LABORATORIES ....... 159
13.4.1 COMPANY OVERVIEW ....... 159
13.4.2 PRODUCTS OFFERED ........ 160
13.4.3 KEY DEVELOPMENTS ........ 160
13.4.4 SWOT ANALYSIS ........ 161
13.4.5 FINANCIAL ANALYSIS ........ 162
13.4.6 KEY STRATEGY ......... 162
13.5 MEDIFORD CORPORATION ........ 163
13.5.1 COMPANY OVERVIEW ....... 163
13.5.2 PRODUCTS OFFERED ........ 164
13.5.3 KEY DEVELOPMENTS ........ 164
13.5.4 SWOT ANALYSIS ........ 165
13.5.5 FINANCIAL ANALYSIS ........ 165
13.5.6 KEY STRATEGY ......... 165
13.6 AURIGENE ......... 166
13.6.1 COMPANY OVERVIEW ....... 166
13.6.2 PRODUCTS OFFERED ........ 167
13.6.3 SWOT ANALYSIS ........ 168
13.6.4 FINANCIAL ANALYSIS ........ 169
13.6.5 KEY STRATEGY ......... 169
13.7 LABCORP...... 170
13.7.1 COMPANY OVERVIEW ....... 170
13.7.2 PRODUCTS OFFERED ........ 170
13.7.3 KEY DEVELOPMENTS ........ 171
13.7.4 SWOT ANALYSIS ........ 171
13.7.5 FINANCIAL ANALYSIS ........ 172
13.7.6 KEY STRATEGY ......... 172
13.8 EVOTEC ........ 173
13.8.1 COMPANY OVERVIEW ....... 173
13.8.2 PRODUCTS OFFERED ........ 174
13.8.3 SWOT ANALYSIS ........ 175
13.8.4 FINANCIAL ANALYSIS ........ 176
13.8.5 KEY STRATEGY ......... 176
13.9 CREATIVE BIOLABS ......... 177
13.9.1 COMPANY OVERVIEW ....... 177
13.9.2 PRODUCTS OFFERED ........ 178
13.9.3 SWOT ANALYSIS ........ 178
13.9.4 KEY STRATEGY ......... 179
13.10 ACCELERA S.R.L .... 180
13.10.1 COMPANY OVERVIEW ....... 180
13.10.2 PRODUCTS OFFERED ........ 181
13.10.3 SWOT ANALYSIS ........ 181
13.10.4 KEY STRATEGY ......... 182
13.11 DATA CITATIONS ....... 183
圖表清單 List of Tables & Figures
LIST OF TABLES
TABLE 1 GLOBAL IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET , BY PRODUCT TYPE, 2019-2035 (USD MILLION) 54
TABLE 2 GLOBAL IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 57
TABLE 3 GLOBAL IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY TECHNOLOGY, 2019-2035 (USD MILLION) 60
TABLE 4 GLOBAL IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY END USER, 2019-2035 (USD MILLION) 63
TABLE 5 GLOBAL IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET , BY SERVICE PROVIDER, 2019-2035 (USD MILLION) 65
TABLE 6 GLOBAL IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET , BY REGION, 2019-2035 (USD MILLION) 67
TABLE 7 NORTH AMERICA: IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 68
TABLE 8 NORTH AMERICA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 69
TABLE 9 NORTH AMERICA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 70
TABLE 10 NORTH AMERICA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY TECHNOLOGY, 2019-2035 (USD MILLION) 71
TABLE 11 NORTH AMERICA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY END USER, 2019-2035 (USD MILLION) 72
TABLE 12 NORTH AMERICA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY SERVICE PROVIDER, 2019-2035 (USD MILLION) 72
TABLE 13 USA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 73
TABLE 14 USA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 74
TABLE 15 USA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY TECHNOLOGY PLATFORM, 2019-2035 (USD MILLION) 74
TABLE 16 USA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY END-USER, 2019-2035 (USD MILLION) 75
TABLE 17 USA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY SERVICE PROVIDER, 2019-2035 (USD MILLION) 75
TABLE 18 CANADA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 75
TABLE 19 CANADA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 76
TABLE 20 CANADA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY TECHNOLOGY PLATFORM, 2019-2035 (USD MILLION) 76
TABLE 21 CANADA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY END USER, 2019-2035 (USD MILLION) 77
TABLE 22 CANADA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY SERVICE PROVIDER, 2019-2035 (USD MILLION) 77
TABLE 23 EUROPE: IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY COUNTRY, 2019-2032 (USD MILLION) 78
TABLE 24 EUROPE IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 79
TABLE 25 EUROPE IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 80
TABLE 26 EUROPE IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY TECHNOLOGY, 2019-2035 (USD MILLION) 81
TABLE 27 EUROPE IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY END USER, 2019-2035 (USD MILLION) 82
TABLE 28 EUROPE IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY SERVICE PROVIDER, 2019-2035 (USD MILLION) 83
TABLE 29 UK IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 84
TABLE 30 UK IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 84
TABLE 31 UK IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY TECHNOLOGY PLATFORM, 2019-2035 (USD MILLION) 85
TABLE 32 UK IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY END USER, 2019-2035 (USD MILLION) 85
TABLE 33 UK IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY SERVICE PROVIDER, 2019-2035 (USD MILLION) 85
TABLE 34 GERMANY IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 86
TABLE 35 GERMANY IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 86
TABLE 36 GERMANY IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY TECHNOLOGY PLATFORM, 2019-2035 (USD MILLION) 87
TABLE 37 GERMANY IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY END USER, 2019-2035 (USD MILLION) 87
TABLE 38 GERMANY IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY SERVICE PROVIDER, 2019-2035 (USD MILLION) 87
TABLE 39 FRANCE IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 88
TABLE 40 FRANCE IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 88
TABLE 41 FRANCE IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY TECHNOLOGY PLATFORM, 2019-2035 (USD MILLION) 89
TABLE 42 FRANCE IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY END USER, 2019-2035 (USD MILLION) 89
TABLE 43 FRANCE IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY SERVICE PROVIDER, 2019-2035 (USD MILLION) 89
TABLE 44 ITALY IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 90
TABLE 45 ITALY IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 90
TABLE 46 ITALY IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY TECHNOLOGY PLATFORM, 2019-2035 (USD MILLION) 91
TABLE 47 ITALY IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY END USER, 2019-2035 (USD MILLION) 91
TABLE 48 ITALY IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY SERVICE PROVIDER, 2019-2035 (USD MILLION) 91
TABLE 49 SPAIN IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 92
TABLE 50 SPAIN IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 92
TABLE 51 SPAIN IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY TECHNOLOGY PLATFORM, 2019-2035 (USD MILLION) 93
TABLE 52 SPAIN IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY END USER, 2019-2035 (USD MILLION) 93
TABLE 53 SPAIN IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY SERVICE PROVIDER, 2019-2035 (USD MILLION) 93
TABLE 54 RUSSIA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 94
TABLE 55 RUSSIA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 94
TABLE 56 RUSSIA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY TECHNOLOGY PLATFORM, 2019-2035 (USD MILLION) 95
TABLE 57 RUSSIA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY END USER, 2019-2035 (USD MILLION) 95
TABLE 58 RUSSIA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY SERVICE PROVIDER, 2019-2035 (USD MILLION) 95
TABLE 59 REST OF EU IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 96
TABLE 60 REST OF EU IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 96
TABLE 61 REST OF EU IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY TECHNOLOGY PLATFORM, 2019-2035 (USD MILLION) 97
TABLE 62 REST OF EU IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY END USER, 2019-2035 (USD MILLION) 97
TABLE 63 REST OF EU IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY SERVICE PROVIDER, 2019-2035 (USD MILLION) 97
TABLE 65 ASIA PACIFIC IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 99
TABLE 66 ASIA PACIFIC IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 100
TABLE 67 ASIA PACIFIC IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY TECHNOLOGY, 2019-2035 (USD MILLION) 101
TABLE 68 ASIA PACIFIC IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY END USER, 2019-2035 (USD MILLION) 102
TABLE 69 ASIA PACIFIC IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY SERVICE PROVIDER, 2019-2035 (USD MILLION) 103
TABLE 70 CHINA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 104
TABLE 71 CHINA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 104
TABLE 72 CHINA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY TECHNOLOGY PLATFORM, 2019-2035 (USD MILLION) 105
TABLE 73 CHINA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY END USER, 2019-2035 (USD MILLION) 105
TABLE 74 CHINA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY SERVICE PROVIDER, 2019-2035 (USD MILLION) 105
TABLE 75 SOUTH KOREA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 106
TABLE 76 SOUTH KOREA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 106
TABLE 77 SOUTH KOREA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY TECHNOLOGY PLATFORM, 2019-2035 (USD MILLION)
TABLE 78 SOUTH KOREA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY END USER, 2019-2035 (USD MILLION) 107
TABLE 79 SOUTH KOREA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY SERVICE PROVIDER, 2019-2035 (USD MILLION) 107
TABLE 80 INDIA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 108
TABLE 81 INDIA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 108
TABLE 82 INDIA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY TECHNOLOGY PLATFORM, 2019-2035 (USD MILLION) 109
TABLE 83 INDIA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY END USER, 2019-2035 (USD MILLION) 109
TABLE 84 INDIA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY SERVICE PROVIDER, 2019-2035 (USD MILLION) 109
TABLE 85 JAPAN IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 110
TABLE 86 JAPAN IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 110
TABLE 87 JAPAN IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY TECHNOLOGY PLATFORM, 2019-2035 (USD MILLION) 111
TABLE 88 JAPAN IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY END USER, 2019-2035 (USD MILLION) 111
TABLE 89 JAPAN IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY SERVICE PROVIDER, 2019-2035 (USD MILLION) 111
TABLE 90 INDONESIA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 112
TABLE 91 INDONESIA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 112
TABLE 92 INDONESIA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY TECHNOLOGY PLATFORM, 2019-2035 (USD MILLION) 113
TABLE 93 INDONESIA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY END USER, 2019-2035 (USD MILLION) 113
TABLE 94 INDONESIA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY SERVICE PROVIDER, 2019-2035 (USD MILLION) 113
TABLE 95 MALAYSIA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 114
TABLE 96 MALAYSIA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 114
TABLE 97 MALAYSIA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY TECHNOLOGY PLATFORM, 2019-2035 (USD MILLION) 115
TABLE 98 MALAYSIA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY END USER, 2019-2035 (USD MILLION) 115
TABLE 99 MALAYSIA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY SERVICE PROVIDER, 2019-2035 (USD MILLION) 115
TABLE 100 THAILAND IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 116
TABLE 101 THAILAND IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 116
TABLE 102 THAILAND IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY TECHNOLOGY PLATFORM, 2019-2035 (USD MILLION) 117
TABLE 103 THAILAND IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY END USER, 2019-2035 (USD MILLION) 117
TABLE 104 THAILAND IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY SERVICE PROVIDER, 2019-2035 (USD MILLION) 117
TABLE 105 REST OF APAC IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 118
TABLE 106 REST OF APAC IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 118
TABLE 107 REST OF APAC IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY TECHNOLOGY PLATFORM, 2019-2035 (USD MILLION)
TABLE 108 REST OF APAC IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY END USER, 2019-2035 (USD MILLION) 119
TABLE 109 REST OF APAC IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY SERVICE PROVIDER, 2019-2035 (USD MILLION) 119
TABLE 111 SOUTH AMERICA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 121
TABLE 112 SOUTH AMERICA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 122
TABLE 113 SOUTH AMERICA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY TECHNOLOGY, 2019-2035 (USD MILLION) 123
TABLE 114 SOUTH AMERICA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY END USER, 2019-2035 (USD MILLION) 124
TABLE 115 SOUTH AMERICA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY SERVICE PROVIDER, 2019-2035 (USD MILLION) 125
TABLE 116 BRAZIL IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 126
TABLE 117 BRAZIL IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 126
TABLE 118 BRAZIL IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY TECHNOLOGY PLATFORM, 2019-2035 (USD MILLION) 127
TABLE 119 BRAZIL IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY END USER, 2019-2035 (USD MILLION) 127
TABLE 120 BRAZIL IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY SERVICE PROVIDER, 2019-2035 (USD MILLION) 127
TABLE 121 MEXICO IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 128
TABLE 122 MEXICO IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 128
TABLE 123 MEXICO IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY TECHNOLOGY PLATFORM, 2019-2035 (USD MILLION) 129
TABLE 124 MEXICO IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY END USER, 2019-2035 (USD MILLION) 129
TABLE 125 MEXICO IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY SERVICE PROVIDER, 2019-2035 (USD MILLION) 129
TABLE 126 ARGENTINA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 130
TABLE 127 ARGENTINA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 130
TABLE 128 ARGENTINA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY TECHNOLOGY PLATFORM, 2019-2035 (USD MILLION) 131
TABLE 129 ARGENTINA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY END USER, 2019-2035 (USD MILLION) 131
TABLE 130 ARGENTINA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY SERVICE PROVIDER, 2019-2035 (USD MILLION)
TABLE 131 REST OF SOUTH AMERICA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION)
TABLE 132 REST OF SOUTH AMERICA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
TABLE 133 REST OF SOUTH AMERICA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY TECHNOLOGY PLATFORM, 2019-2035 (USD MILLION)
TABLE 134 REST OF SOUTH AMERICA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY END USER, 2019-2035 (USD MILLION) 133
TABLE 135 REST OF SOUTH AMERICA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY SERVICE PROVIDER, 2019-2035 (USD MILLION)
TABLE 137 MEA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION)
TABLE 138 MEA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
TABLE 139 MEA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY TECHNOLOGY, 2019-2035 (USD MILLION)
TABLE 140 MEA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY END USER, 2019-2035 (USD MILLION)
TABLE 141 MEA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY SERVICE PROVIDER, 2019-2035 (USD MILLION)
TABLE 142 GCC COUNTRIES IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION)
TABLE 143 GCC COUNTRIES IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
TABLE 144 GCC COUNTRIES IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY TECHNOLOGY PLATFORM, 2019-2035 (USD MILLION)
TABLE 145 GCC COUNTRIES IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY END USER, 2019-2035 (USD MILLION)
TABLE 146 GCC COUNTRIES IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY SERVICE PROVIDER, 2019-2035 (USD MILLION) 141
TABLE 147 SOUTH AFRICA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION)
TABLE 148 SOUTH AFRICA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
TABLE 149 SOUTH AFRICA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY TECHNOLOGY PLATFORM, 2019-2035 (USD MILLION)
TABLE 150 SOUTH AFRICA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY END USER, 2019-2035 (USD MILLION)
TABLE 151 SOUTH AFRICA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY SERVICE PROVIDER, 2019-2035 (USD MILLION)
TABLE 152 REST OF MEA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION)
TABLE 153 REST OF MEA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
TABLE 154 REST OF MEA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY TECHNOLOGY PLATFORM, 2019-2035 (USD MILLION)
TABLE 155 REST OF MEA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY END USER, 2019-2035 (USD MILLION)
TABLE 156 REST OF MEA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY SERVICE PROVIDER, 2019-2035 (USD MILLION)
TABLE 157 EUROFINS: PRODUCT OFFERED
TABLE 158 EUROFINS: KEY DEVELOPMENTS
TABLE 159 ICE BIOSCIENCE: PRODUCT OFFERED
TABLE 160 WUXI BIOLOGY: PRODUCT OFFERED
TABLE 161 CHARLES RIVER LABORATORIES.: PRODUCT OFFERED
TABLE 162 PANASONIC ENERGY CO., LTD. CHARLES RIVER LABORATORIES: KEY DEVELOPMENTS
TABLE 163 MEDIFORD CORPORATION: PRODUCT OFFERED
TABLE 164 MEDIFORD CORPORATION.: KEY DEVELOPMENTS
TABLE 165 AURIGENE: PRODUCT OFFERED
TABLE 166 LABCORP: PRODUCT OFFERED
TABLE 167 LABCORP.: KEY DEVELOPMENTS
TABLE 168 EVOTEC: PRODUCT OFFERED
TABLE 169 CREATIVE BIOLABS: PRODUCT OFFERED
TABLE 170 ACCELERA S.R.L: PRODUCT OFFERED
LIST OF FIGURES
FIGURE 1 GLOBAL IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET SEGMENT 27
FIGURE 2 GLOBAL IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET: GROWTH FACTOR ANALYSIS 42
FIGURE 3 DRIVER IMPACT ANALYSIS (2018-2035) 45
FIGURE 4 RESTRAINT IMPACT ANALYSIS (2018-2035) 47
FIGURE 5 SUPPLY CHAIN ANALYSIS 49
FIGURE 6 PORTER’S FIVE FORCES MODEL: GLOBAL IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET 51
FIGURE 7 GLOBAL IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET , BY PRODUCT TYPE, 2024 (% SHARE) 54
FIGURE 8 GLOBAL IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY APPLICATION, 2024 (% SHARE) 58
FIGURE 9 GLOBAL IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET , BY TECHNOLOGY, 2024 (% SHARE) 61
FIGURE 10 GLOBAL IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET , BY END USER, 2024 (% SHARE) 63
FIGURE 11 GLOBAL IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET , BY SERVICE PROVIDER, 2024 (% SHARE) 65
FIGURE 12 GLOBAL IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET , BY REGION, 2024 (% SHARE) 68
FIGURE 13 NORTH AMERICA: IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET SHARE, BY COUNTRY, 2024 (% SHARE) 69
FIGURE 14 NORTH AMERICA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY PRODUCT TYPE, 2024 (% SHARE) 69
FIGURE 15 NORTH AMERICA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY APPLICATION, 2024 (% SHARE) 70
FIGURE 16 NORTH AMERICA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY TECHNOLOGY, 2024 (% SHARE) 71
FIGURE 17 NORTH AMERICA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY END USER, 2024 (% SHARE) 72
FIGURE 18 NORTH AMERICA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY SERVICE PROVIDER, 2024 (% SHARE) 73
FIGURE 19 EUROPE: IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET SHARE, BY COUNTRY, 2024 (% SHARE) 79
FIGURE 20 EUROPE IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY PRODUCT TYPE, 2024 (% SHARE) 80
FIGURE 21 EUROPE IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY APPLICATION, 2024 (% SHARE) 81
FIGURE 22 EUROPE IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY TECHNOLOGY, 2024 (% SHARE) 82
FIGURE 23 EUROPE IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY END USER, 2024 (% SHARE) 83
FIGURE 24 EUROPE IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY SERVICE PROVIDER, 2024 (% SHARE) 83
FIGURE 25 ASIA PACIFIC: IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET SHARE, BY COUNTRY, 2024 (% SHARE) 99
FIGURE 26 ASIA PACIFIC IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY PRODUCT TYPE, 2024 (% SHARE) 100
FIGURE 27 ASIA PACIFIC IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY APPLICATION, 2024 (% SHARE) 101
FIGURE 28 ASIA PACIFIC IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY TECHNOLOGY, 2024 (% SHARE) 102
FIGURE 29 ASIA PACIFIC IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY END USER, 2024 (% SHARE) 103
FIGURE 30 ASIA PACIFIC IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY SERVICE PROVIDER, 2024 (% SHARE) 103
FIGURE 31 SOUTH AMERICA: IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET SHARE, BY COUNTRY, 2024 (% SHARE) 121
FIGURE 32 SOUTH AMERICA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY PRODUCT TYPE, 2024 (% SHARE) 122
FIGURE 33 SOUTH AMERICA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY APPLICATION, 2024 (% SHARE) 123
FIGURE 34 SOUTH AMERICA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY TECHNOLOGY, 2024 (% SHARE) 124
FIGURE 35 SOUTH AMERICA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY END USER, 2024 (% SHARE) 125
FIGURE 36 SOUTH AMERICA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY SERVICE PROVIDER, 2024 (% SHARE) 125
FIGURE 38 MEA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY PRODUCT TYPE, 2024 (% SHARE) 136
FIGURE 39 MEA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY APPLICATION, 2024 (% SHARE) 137
FIGURE 40 MEA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY TECHNOLOGY, 2024 (% SHARE) 138
FIGURE 41 MEA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY END USER, 2024 (% SHARE) 139
FIGURE 42 MEA IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET, BY SERVICE PROVIDER, 2024 (% SHARE) 139
FIGURE 43 GLOBAL IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET : COMPETITIVE ANALSIS, 2024 147
FIGURE 44 COMPETITOR DASHBOARD: GLOBAL IN VITRO SAFETY PHARMACOLOGY PROFILING MARKET 148
FIGURE 45 EUROFINS: SWOT ANALYSIS 151
FIGURE 46 ICE BIOSCIENCE: SWOT ANALYSIS 154
FIGURE 47 WUXI BIOLOGY: SWOT ANALYSIS 157
FIGURE 48 CHARLES RIVER LABORATORIES: SWOT ANALYSIS 161
FIGURE 49 PANASONIC ENERGY CO., LTD MEDIFORD CORPORATION: SWOT ANALYSIS 165
FIGURE 50 AURIGENE: SWOT ANALYSIS 168
FIGURE 51 LABCORP: SWOT ANALYSIS 171
FIGURE 52 EVOTEC: SWOT ANALYSIS 175
FIGURE 53 CREATIVE BIOLABS: SWOT ANALYSIS 178
FIGURE 54 ACCELERA S.R.L: SWOT ANALYSIS 181
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 Market Research Future 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們